timothy sykes logo
EYPT Stock Plunges As LUGANO Miss Resets High-Risk Catalyst Trade Thumbnail
G Google News

EYPT Stock Plunges As LUGANO Miss Resets High-Risk Catalyst Trade

TIM SYKES•UPDATED AUG. 18, 2026, 12:33 PM ET
Reviewed by Bryce Tuoheyand Fact-checked by Matt Monaco

EyePoint Inc. stocks have been trading up by 10.37 percent after positive clinical trial news bolstered investor optimism.

Key Takeaways For EYPT Traders

  • Phase 3 LUGANO in wet AMD missed its primary vision endpoint, but an adjusted analysis plus strong secondary data still showed DURAVYU competitive versus aflibercept with lower treatment burden.
  • After the miss, EYPT collapsed about 69% to $4.57, and JPMorgan cut its rating to Neutral even as the Street’s average target sits near $38.58.
  • Multiple firms — Laidlaw, Jefferies, H.C. Wainwright, Citi, and Cantor — kept Buy/Overweight calls on EyePoint Pharmaceuticals with targets from $8 to $55.
  • The LUCIA Phase 3 wet AMD trial and two DME Phase 3 programs remain fully enrolled, with topline data and a possible NDA clustered in 2026–2027.
  • Q2 revenue of $507,000 topped expectations, but EYPT posted a wider-than-forecast loss of ($1.09) per share as spending on late-stage trials climbed.

Candlestick Chart

Live Update At 12:32:45 EDT: On Tuesday, August 18, 2026 EyePoint Inc. stock [NASDAQ: EYPT] is trending up by 10.37%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

EYPT has turned into a textbook biotech rollercoaster. Just days ago, EyePoint Pharmaceuticals was trading near $14. Then the LUGANO Phase 3 headline hit, the primary endpoint was missed, and traders watched the stock get smashed down to the mid‑$4s — a drawdown of roughly 69% from recent levels.

Under the hood, EYPT is still a classic development-stage name. Q2 revenue was only $507,000, which did beat the $390,000 estimate but is tiny compared with the company’s $31.37M trailing revenue base. The real story is spending. EYPT posted a Q2 loss of ($1.09) per share versus the ($0.96) Street forecast, with research and development running over $83.6M for the period.

More Breaking News

Cash matters here. The balance sheet shows about $110.46M in cash and $180.47M in total cash and short-term investments as of 2026/06/30, paired with a current ratio of 4.5, so EyePoint has runway but continues to burn cash — free cash flow was around negative $63.55M for the quarter. For traders, that means EYPT’s chart will react far more to each DURAVYU data headline than to small quarterly revenue beats.

Why Traders Are Watching EYPT After The Crash

EYPT is now one of those broken charts that still attracts aggressive catalyst traders. The LUGANO Phase 3 data in wet age‑related macular degeneration is the pivot point. On the surface, the trial failed: DURAVYU did not meet its pre‑specified primary BCVA non‑inferiority endpoint when all patients were included. That alone explains why EYPT imploded from the teens to the single digits in a straight‑down move.

But the details are what keep traders glued to this ticker. EyePoint Pharmaceuticals reported that a small, asymmetric 4% cohort had vision loss considered unrelated to wet AMD. When that atypical group was excluded in an ad hoc analysis, DURAVYU showed non‑inferiority versus on‑label aflibercept. Secondary endpoints looked even stronger: roughly a 42% reduction in treatment burden, high supplement‑free rates, durable six‑month dosing, and a clean safety and anatomic profile.

Wall Street is split, which is exactly the kind of tension momentum traders like to see. JPMorgan bailed on its Overweight stance, moving to Neutral after the selloff, even as the average target across firms still sits around $38.58. At the same time, Laidlaw called the LUGANO miss a likely one‑off statistical issue, trimming its target slightly to $48 but sticking with a Buy on EYPT. Jefferies slashed its target from $30 to $8 yet also kept a Buy label, framing EYPT as a reset, high‑beta bet with LUCIA as the next major readout.

Meanwhile, earlier in the catalyst cycle, Citi had put EyePoint on an “upside 90‑day catalyst watch” with a $35 target, and Cantor Fitzgerald even raised its target to $55 and reiterated Overweight. Add H.C. Wainwright at $27 with a Buy, and you have a wide band of targets — from $8 all the way to $55 — on a stock last seen near $5. For short‑term traders, that spread screams uncertainty, volatility, and opportunity.

Conclusion

Right now, EYPT is trading more on emotion and headlines than on fundamentals. The daily chart shows the story in one glance: a steady grind around $12–$14 through late July, then a cliff dive to sub‑$5 on 2026/08/17. The next day brought a reflex bounce toward $4.90, and on 2026/08/18 the stock pushed into the mid‑$5s, with intraday action between about $5.21 and $5.49 and tight five‑minute candles showing consolidation after panic.

Underneath that price action, EyePoint Pharmaceuticals still has real catalysts. The LUCIA Phase 3 trial in wet AMD is fully enrolled, with topline data expected in Q4 2026 and a possible NDA filing in 2027/01–2027/06. Two fully enrolled Phase 3 DME trials, COMO and CAPRI, line up more readouts in 2027. If those confirm the strong treatment‑burden reduction and safety seen in LUGANO’s secondary data, the current $4–$6 trading range may look very different down the road. If they fail, today’s bounce will look like just another dead‑cat move on the long‑term chart.

For active traders, EYPT is a pure “plan your trade, trade your plan” setup. Size and risk control matter more than opinions about the science. As Tim Sykes likes to tell students, “Volatile stocks are great teachers — if you respect the risk and cut losses fast.” As millionaire penny stock trader and teacher Tim Sykes says, “Cut losses quickly, let profits ride, and don’t overtrade.” EYPT fits that mold perfectly right now, and any trader stepping into this name should treat it as a high‑risk, news‑driven swing, not a comfortable long‑term hold.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”